- Home
- IIIV vs PVLA Comparison
IIIV vs PVLA Comparison
Compare IIIV & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- PVLA
- Stock Information
- Founded
- IIIV 2012
- PVLA 2015
- Country
- IIIV United States
- PVLA United States
- Employees
- IIIV N/A
- PVLA N/A
- Industry
- IIIV EDP Services
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- IIIV Technology
- PVLA Health Care
- Exchange
- IIIV Nasdaq
- PVLA Nasdaq
- Market Cap
- IIIV 720.4M
- PVLA 604.2M
- IPO Year
- IIIV 2018
- PVLA N/A
- Fundamental
- Price
- IIIV $29.24
- PVLA $77.19
- Analyst Decision
- IIIV Buy
- PVLA Strong Buy
- Analyst Count
- IIIV 6
- PVLA 13
- Target Price
- IIIV $34.33
- PVLA $94.92
- AVG Volume (30 Days)
- IIIV 155.6K
- PVLA 167.7K
- Earning Date
- IIIV 11-17-2025
- PVLA 11-11-2025
- Dividend Yield
- IIIV N/A
- PVLA N/A
- EPS Growth
- IIIV N/A
- PVLA N/A
- EPS
- IIIV 5.56
- PVLA N/A
- Revenue
- IIIV $248,271,000.00
- PVLA N/A
- Revenue This Year
- IIIV N/A
- PVLA N/A
- Revenue Next Year
- IIIV $3.86
- PVLA N/A
- P/E Ratio
- IIIV $5.28
- PVLA N/A
- Revenue Growth
- IIIV 25.08
- PVLA N/A
- 52 Week Low
- IIIV $22.20
- PVLA $11.17
- 52 Week High
- IIIV $33.97
- PVLA $83.00
- Technical
- Relative Strength Index (RSI)
- IIIV 34.23
- PVLA 53.80
- Support Level
- IIIV $29.19
- PVLA $73.70
- Resistance Level
- IIIV $30.09
- PVLA $82.19
- Average True Range (ATR)
- IIIV 1.03
- PVLA 5.12
- MACD
- IIIV -0.30
- PVLA -0.43
- Stochastic Oscillator
- IIIV 9.42
- PVLA 47.44
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.